📊 MRK Key Takeaways
Is Merck & Co., Inc. (MRK) a Good Investment?
Merck is operating at a critical profitability crisis with -$4.2B net income, -26.0% net margin, and inability to cover interest from operations (-11.7x coverage). While positive free cash flow ($2.9B) provides near-term survival cushion, the combination of severe losses, high leverage (1.02x debt-to-equity), and negative returns on equity/assets signals fundamental operational distress requiring urgent resolution.
Merck shows high-quality profitability with a 32.4% operating margin, 28.1% net margin, 34.7% ROE, and strong interest coverage, indicating an efficient and financially resilient business. Free cash flow of $12.36B and solid liquidity support balance sheet flexibility, while modest 1.3% revenue growth suggests the core business remains stable but not currently in a high-growth phase.
Why Buy Merck & Co., Inc. Stock? MRK Key Strengths
- Positive free cash flow of $2.9B despite massive accounting losses suggests underlying business stability
- Large asset base of $128.7B indicates substantial portfolio of productive assets and valuable IP
- Improving EPS trajectory (+8.0% YoY) and modest revenue growth (+1.3% YoY) suggest potential stabilization
- Excellent profitability, with very strong operating and net margins for a large pharmaceutical company
- Healthy financial position, including 1.54x current ratio, 1.30x quick ratio, and 69.5x interest coverage
- Robust cash generation, with $16.47B operating cash flow and $12.36B free cash flow
MRK Stock Risks: Merck & Co., Inc. Investment Risks
- Operating income of -$3.5B and net margin of -26.0% indicate severe operational distress beyond temporary charges
- Unable to cover interest expenses from operations with -11.7x interest coverage and high debt load of $46.7B relative to $5.3B cash
- Debt-to-equity ratio of 1.02x combined with negative profitability creates unsustainable capital structure and refinancing risk
- Revenue growth is modest at 1.3% YoY, which may limit upside if the product portfolio does not reaccelerate
- Leverage is meaningful, with $46.75B of long-term debt and debt-to-equity of 0.89x
- Pharmaceutical fundamentals can be vulnerable to product concentration, patent expirations, and pipeline execution risk
Key Metrics to Watch
- Return to operating profitability and positive net margin trajectory
- Interest coverage ratio improvement and debt reduction relative to equity
- Sustainability of operating cash flow generation and underlying business cash conversion
- Revenue growth and diluted EPS growth
- Free cash flow generation and debt levels
Merck & Co., Inc. (MRK) Financial Metrics & Key Ratios
💡 AI Analyst Insight
Merck & Co., Inc. presents a mixed fundamental picture. Review the detailed metrics above to form your own investment thesis.
MRK Profit Margin, ROE & Profitability Analysis
MRK vs Healthcare Sector: How Merck & Co., Inc. Compares
How Merck & Co., Inc. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is Merck & Co., Inc. Stock Overvalued? MRK Valuation Analysis 2026
Based on fundamental analysis, Merck & Co., Inc. shows some fundamental concerns relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
Merck & Co., Inc. Balance Sheet: MRK Debt, Cash & Liquidity
MRK Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: Merck & Co., Inc.'s revenue has grown significantly by 33% over the 5-year period, indicating strong business expansion. The most recent EPS of $0.14 reflects profitable operations.
MRK Revenue Growth, EPS Growth & YoY Performance
MRK Quarterly Earnings & Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2026 | $15.5B | -$4.2B | $-1.72 |
| Q3 2025 | $16.7B | $3.2B | $1.24 |
| Q2 2025 | $15.8B | $4.4B | $1.76 |
| Q1 2025 | $15.5B | $4.8B | $1.87 |
| Q3 2024 | $16.0B | $1.6B | $0.62 |
| Q2 2024 | $15.0B | -$3.2B | $-1.24 |
| Q1 2024 | $14.5B | $2.8B | $1.11 |
| Q3 2023 | $15.0B | $1.6B | $0.62 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
Merck & Co., Inc. Dividends, Buybacks & Capital Allocation
MRK SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for Merck & Co., Inc. (CIK: 0000310158)
📋 Recent SEC Filings
❓ Frequently Asked Questions about MRK
What is the AI rating for MRK?
Merck & Co., Inc. (MRK) has a Combined AI Rating of HOLD from Claude (SELL) and ChatGPT (BUY) with 78% combined confidence, based on fundamental analysis of SEC EDGAR filings.
What are MRK's key strengths?
Claude: Positive free cash flow of $2.9B despite massive accounting losses suggests underlying business stability. Large asset base of $128.7B indicates substantial portfolio of productive assets and valuable IP. ChatGPT: Excellent profitability, with very strong operating and net margins for a large pharmaceutical company. Healthy financial position, including 1.54x current ratio, 1.30x quick ratio, and 69.5x interest coverage.
What are the risks of investing in MRK?
Claude: Operating income of -$3.5B and net margin of -26.0% indicate severe operational distress beyond temporary charges. Unable to cover interest expenses from operations with -11.7x interest coverage and high debt load of $46.7B relative to $5.3B cash. ChatGPT: Revenue growth is modest at 1.3% YoY, which may limit upside if the product portfolio does not reaccelerate. Leverage is meaningful, with $46.75B of long-term debt and debt-to-equity of 0.89x.
What is MRK's revenue and growth?
Merck & Co., Inc. reported revenue of $16.3B.
Does MRK pay dividends?
Merck & Co., Inc. pays dividends, with $2,105.0M distributed to shareholders in the trailing twelve months.
Where can I find MRK SEC filings?
Official SEC filings for Merck & Co., Inc. (CIK: 0000310158) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is MRK's EPS?
Merck & Co., Inc. has a diluted EPS of $-1.72.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.
Is MRK a good stock to buy right now?
Based on our AI fundamental analysis in May 2026, Merck & Co., Inc. has a HOLD rating with 78% confidence. Review the strengths and risks sections above before making a decision. This is not investment advice.
Is MRK stock overvalued or undervalued?
Valuation metrics for MRK: ROE of -9.2% (sector avg: 15%), net margin of -26.0% (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
Should I buy MRK stock in 2026?
Our dual AI analysis gives Merck & Co., Inc. a combined HOLD rating for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is MRK's free cash flow?
Merck & Co., Inc.'s operating cash flow is $3.9B, with capital expenditures of $991.0M. FCF margin is 18.0%.
How does MRK compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin -26.0% (avg: 12%), ROE -9.2% (avg: 15%), current ratio 1.30 (avg: 2).